These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 17253432

  • 1. Predicting a relapse of Graves' hyperthyroidism in adults during the early phase of treatment with anti-thyroid drugs.
    Jonas M, Ambroziak U, Bednarczuk T, Nauman J.
    Endokrynol Pol; 2006; 57(6):596-604. PubMed ID: 17253432
    [Abstract] [Full Text] [Related]

  • 2. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N, Yamashiro K, Komiya I, Ochi Y, Sato Y, Nagata A.
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [Abstract] [Full Text] [Related]

  • 3. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D, Massart C.
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
    [Abstract] [Full Text] [Related]

  • 4. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS, Zwicker H, Abbott EC, Douglas R, Givner ML, Gupta MK, Lehmann L, Reddy S, Salisbury SR, Shlossberg AH, Tan MH, York SE.
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [Abstract] [Full Text] [Related]

  • 5. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
    Ohara N, Kaneko M, Kitazawa M, Uemura Y, Minagawa S, Miyakoshi M, Kaneko K, Kamoi K.
    J Med Case Rep; 2017 Feb 06; 11(1):32. PubMed ID: 28162094
    [Abstract] [Full Text] [Related]

  • 6. The prevalence of transient thyrotoxicosis after antithyroid drug therapy in patients with Graves' disease.
    Kubota S, Takata K, Arishima T, Ohye H, Nishihara E, Kudo T, Ito M, Fukata S, Amino N, Miyauchi A.
    Thyroid; 2008 Jan 06; 18(1):63-6. PubMed ID: 18302519
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK, Yoo WS, Kim DW, Chung HK.
    Thyroid; 2010 Sep 06; 20(9):949-54. PubMed ID: 20629556
    [Abstract] [Full Text] [Related]

  • 9. Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients.
    Brokken LJ, Wiersinga WM, Prummel MF.
    J Clin Endocrinol Metab; 2003 Sep 06; 88(9):4135-8. PubMed ID: 12970276
    [Abstract] [Full Text] [Related]

  • 10. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B, Hoermann R, Roggenbuck U, Hahn S, Mann K, Janssen OE, Basedow Study Group.
    Thyroid; 2005 Sep 06; 15(9):1047-54. PubMed ID: 16187913
    [Abstract] [Full Text] [Related]

  • 11. Valuable predictive features of relapse of Graves' disease after antithyroid drug treatment.
    Liu X, Shi B, Li H.
    Ann Endocrinol (Paris); 2015 Dec 06; 76(6):679-83. PubMed ID: 26514949
    [Abstract] [Full Text] [Related]

  • 12. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ, Lee BW, Kim JY, Jung JH, Min YK, Lee MS, Lee MK, Kim KW, Chung JH.
    Thyroid; 2006 Dec 06; 16(12):1251-7. PubMed ID: 17199435
    [Abstract] [Full Text] [Related]

  • 13. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment.
    Giuliani C, Cerrone D, Harii N, Thornton M, Kohn LD, Dagia NM, Bucci I, Carpentieri M, Di Nenno B, Di Blasio A, Vitti P, Monaco F, Napolitano G.
    J Clin Endocrinol Metab; 2012 Jul 06; 97(7):E1080-7. PubMed ID: 22492869
    [Abstract] [Full Text] [Related]

  • 14. Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease.
    Zimmermann-Belsing T, Nygaard B, Rasmussen AK, Feldt-Rasmussen U.
    Eur J Endocrinol; 2002 Feb 06; 146(2):173-7. PubMed ID: 11834425
    [Abstract] [Full Text] [Related]

  • 15. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.
    Glinoer D, de Nayer P, Bex M, Belgian Collaborative Study Group on Graves' Disease.
    Eur J Endocrinol; 2001 May 06; 144(5):475-83. PubMed ID: 11331213
    [Abstract] [Full Text] [Related]

  • 16. A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs.
    Kawai K, Tamai H, Matsubayashi S, Mukuta T, Morita T, Kubo C, Kuma K.
    Clin Endocrinol (Oxf); 1995 Nov 06; 43(5):551-6. PubMed ID: 8548939
    [Abstract] [Full Text] [Related]

  • 17. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study.
    Cappelli C, Gandossi E, Castellano M, Pizzocaro C, Agosti B, Delbarba A, Pirola I, De Martino E, Rosei EA.
    Endocr J; 2007 Dec 06; 54(5):713-20. PubMed ID: 17675761
    [Abstract] [Full Text] [Related]

  • 18. Serum free triiodothyronine to free thyroxine ratio enables early prediction of the outcome of antithyroid drug therapy in patients with Graves' hyperthyroidism.
    Tajiri J, Noguchi S, Morita M, Tamaru M, Murakami N, Kato R.
    Endocrinol Jpn; 1991 Dec 06; 38(6):683-7. PubMed ID: 1726635
    [Abstract] [Full Text] [Related]

  • 19. Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease.
    Nakazato N, Yoshida K, Mori K, Kiso Y, Sayama N, Tani JI, Nakagawa Y, Ito S.
    Thyroid; 1999 Aug 06; 9(8):775-9. PubMed ID: 10482369
    [Abstract] [Full Text] [Related]

  • 20. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs.
    Michelangeli V, Poon C, Taft J, Newnham H, Topliss D, Colman P.
    Thyroid; 1998 Feb 06; 8(2):119-24. PubMed ID: 9510119
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.